Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

S. Buti, M. Bersanelli, F. Perrone, S. Bracarda, M. Di Maio, R. Giusti, O. Nigro, D.L. Cortinovis, J.G.J.V. Aerts, G. Guaitoli, F. Barbieri, M.G. Ferrara, E. Bria, F. Grossi, C. Bareggi, R. Berardi, M. Torniai, L. Cantini, V. Sforza, C. GenovaR. Chiari, D. Rocco, L. Della Gravara, S. Gori, M. De Tursi, P. Di Marino, G. Mansueto, F. Zoratto, M. Filetti, F. Citarella, M. Russano, F. Mazzoni, M.C. Garassino, A. De Toma, D. Signorelli, A. Gelibter, M. Siringo, A. Follador, R. Bisonni, A. Tuzi, G. Minuti, L. Landi, S. Ricciardi, M.R. Migliorino, F. Tabbò, E. Olmetto, G. Metro, V. Adamo, A. Russo, G.P. Spinelli, G.L. Banna, A. Addeo, A. Friedlaender, K. Cannita, G. Porzio, C. Ficorella, L. Carmisciano, D.J. Pinato, G. Mazzaschi, M. Tiseo, A. Cortellini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)224-231
Number of pages8
JournalEuropean Journal of Cancer
Volume150
DOIs
Publication statusPublished - 2021

Keywords

  • Concomitant medications
  • First-line
  • Immunotherapy
  • Non–small-cell lung cancer
  • Pembrolizumab
  • Predictive score
  • antineoplastic agent
  • corticosteroid
  • pembrolizumab
  • advanced cancer
  • aged
  • Article
  • cancer immunotherapy
  • case control study
  • clinical outcome
  • cohort analysis
  • controlled study
  • female
  • follow up
  • high risk population
  • human
  • major clinical study
  • male
  • non small cell lung cancer
  • overall survival
  • priority journal
  • progression free survival

Cite this